Carisma Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $3,385 | $9,197 | $3,397 | $4,289 |
Gross Profit | 3,385 | 8,942 | 1,704 | |
EBITDA | -12,407 | -11,415 | -17,817 | |
EBIT | -13,144 | -11,670 | -19,510 | |
Net Income | -12,702 | -11,162 | -18,978 | -20,958 |
Net Change In Cash | 3,385 | 9,197 | 3,397 | 4,289 |
Free Cash Flow | -13,020 | -16,226 | -22,442 | -16,658 |
Cash | 26,881 | 40,362 | 56,515 | 77,605 |
Basic Shares | 41,543 | 41,543 | 40,938 | 40,609 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $14,919 | $9,834 | $26,544 | $11,236 |
Gross Profit | -59,206 | 3,744 | 26,459 | 11,236 |
EBITDA | -85,894 | -51,991 | -40,112 | -27,930 |
EBIT | -88,731 | -58,081 | -40,197 | -28,052 |
Net Income | -86,879 | -61,226 | -40,774 | -28,320 |
Net Change In Cash | 14,919 | 9,834 | 26,544 | 11,236 |
Free Cash Flow | -82,309 | -12,226 | -39,199 | -27,452 |
Cash | 77,605 | 24,194 | 28,551 | 51,788 |
Basic Shares | 33,524 | 106 | 9,116 | 5,911 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.31 |
2024-06-30 | -$0.27 |
2024-03-31 | -$0.46 |
2023-12-31 | -$0.52 |
